Cases of immune-related nephritis have been reported in cancer patients receiving TECENTRIQ treatment. As of 31 May 2018, there were a total of 28 cases including 13 biopsy confirmed cases in which atezolizumab played a potential role in the development of nephritis. Two of the 28 cases were reported in Canada. Both patients recovered with corticosteroid treatment.
RecallTracker